3 Newton Executive Park, Suite 101
6 articles with Macrolide Pharmaceuticals
Inthera Bioscience AG Expands Management Team with Seasoned Professionals and Secures €4.7 Million Second Tranche of €9.6 Million Series A Financing
Inthera Bioscience AG today announced that three senior Pharma and Biotech Industry members joined its management team.
Macrolide announced that Mahesh Karande has joined the company as President and CEO
Macrolide Pharmaceuticals Announces Up to $6.8 Million Award from CARB-X to Develop Macrolide Antibiotics with Gram-Negative Activity
Macrolide Pharmaceuticals announced it has been granted a CARB-X award of up to $6.8M to support the development of a novel fully synthetic, orally available macrolide antibiotic with Gram-negative activity, with the aim of treating serious infections including drug-resistant complicated urinary tract infections (cUTI).
Macrolide Pharmaceuticals Presents New Data on Tool to Differentiate Macrolide Antibacterial Drugs by Risk of Liver Toxicity
The company’s approach aids in distinguishing liver-toxic ketolide antibiotics from safer macrolides that are widely used in the community and hospital settings.
Macrolide Scientific Founder Publishes New Findings In Nature On Groundbreaking Technology For Novel Macrolide Antibiotics